Introduction {#s1}
============

Asthma is a heterogeneous disease, usually characterised by chronic airway inflammation and reversible airflow limitation. Current asthma treatment guidelines are based on the Global Initiative for Asthma (GINA) recommendations, which suggest a stepwise approach in asthma treatment. Most steps involve treatment with inhaled corticosteroids (ICS). Long-acting β~2~-agonists (LABA) are suggested at increasing severity. In severe asthma, add-on treatment includes long-acting muscarinic antagonist and biological agents. Add-on treatment with biological agents is based on inflammatory phenotyping, whereas GINA guidelines are based on asthma symptoms only and do not take levels of airway inflammation into account \[[@C1]\].

Recent research aims to determine the clinical use of asthma biomarkers in a manner of personalised therapy, which will need a shift in asthma treatment from a symptom-based to a precision medicine approach. Different asthma phenotypes have been described based on clinical characteristics and general inflammatory mechanisms. The most well-established cellular mechanism is eosinophilic (T-helper 2 (Th2) high) airway inflammation in asthma \[[@C2]\]. This Th2 airway inflammation is characterised by elevated levels of cytokines such as interleukin (IL)-4, IL-5, IL-13, immunoglobulin (Ig)E, and high blood or sputum eosinophilia \[[@C3]\]. Asthmatic patients with eosinophilic airway inflammation are more ICS sensitive and have a good and rapid response to this treatment \[[@C3]--[@C5]\].

An association between sputum eosinophils and exhaled nitric oxide fraction (*F*~eNO~) has been reported \[[@C6]--[@C8]\]. Measurement of sputum eosinophils is comprehensive, expensive and not easy to perform in daily clinic, whereas level of airway inflammation measured by *F*~eNO~ \[[@C6]\] is standardised, easy to perform and with an immediate result, and hence very useable in the daily clinic. The clinical use of this measurement is still a conflicting subject. It is established that *F*~eNO~ can be used as a diagnostic tool \[[@C9]\], but the use of *F*~eNO~ as a guide for monitoring airway inflammation remains a subject of research. Previous studies of the use of *F*~eNO~-based treatment algorithms are conflicting \[[@C10], [@C11]\]. However, as elevated levels of *F*~eNO~ are correlated to airway hyperresponsiveness (AHR) towards mannitol in both selected and unselected groups of patients \[[@C12], [@C13]\]. It is suggested that asthmatic patients with high *F*~eNO~, sputum eosinophilia or AHR towards mannitol are more responsive to steroid treatment.

We tested the hypothesis that a *F*~eNO-~based treatment algorithm would improve asthma control significantly, indicated by decreased levels of AHR, compared to a symptom-based treatment algorithm.

Methods {#s2}
=======

Study design and participants {#s2a}
-----------------------------

80 asthmatic adult patients (aged ≥18 years) were included in a double-blinded, parallel, randomised controlled trial (RCT) of *F*~eNO~ guided anti-asthma therapy *versus* symptom guided asthma management over study period of 9 months at the Respiratory Research Unit at Bispebjerg Hospital (Copenhagen, Denmark). Inclusion took place from September 2012 to June 2015 and included patients were recruited either from a private asthma clinic outside the hospital or from the hospital-based outpatient clinic. Patients with a doctor\'s diagnosis of asthma, including AHR (*i.e.* a provocative dose causing a 15% fall in forced expiratory volume in 1 s (PD15) \<635 mg) to mannitol and asthma symptoms were included ([figure 1](#F1){ref-type="fig"}). Participants could not have other pulmonary diseases and female participants should be using contraception and not be pregnant. After enrolment, participants were randomly assigned, using a computer-generated block randomisation with a block size of 10, to one of two treatment arms: 1) management based on the level of *F*~eNO~ ([tables 1](#TB1){ref-type="table"} and [2](#TB2){ref-type="table"}); or 2) management based on the level of symptoms indicated by the Asthma Control Questionnaire (ACQ) ([table 3](#TB3){ref-type="table"}), using the algorithm suggested by P[owell]{.smallcaps} *et al*. \[[@C14]\]. In this study, a physician who was blinded to the treatment arms was responsible for the randomisation schedule, as well as the up and down titration of medication for each participant according to the algorithm and had no access to the participants at any visit or to the patient records. The physician sent a text message with the relevant medication adjustment to the research assistant, after which the research assistant informed the relevant participant by text message or email. The study was a "real life" study, thus a time deviation between visits was anticipated. This deviation was sought to be no more than ±14 days. All participants provided informed consent. All case report forms were evaluated by an independent good clinical practice unit and the study was approved by the local ethical committee (H-1-2012-106), [Clinicaltrials.gov](Clinicaltrials.gov) (NCT01978678) and EudraCT (2013-004905-15).

![Flow chart of the trial profile. Patients with a positive mannitol test were included. *F*~eNO~: exhaled nitric oxide fraction; ACQ: Asthma Control Questionnaire.](00147-2017.01){#F1}

###### 

Exhaled nitric oxide fraction (*F*~eNO~) algorithm

                 ***F***~**eNO**~ **concentration ppb**   **ICS dose change**       **ACQ score**        **β~2~-agonist dose change**
  ------------- ---------------------------------------- --------------------- ------------------------ ------------------------------
  **Level 1**                     \>29                       ↑ 1 ICS step                ≤1.5                     No change
  **Level 2**                    16--29                        No change                \>1.5                   ↑ 1 LABA step
  **Level 3**                     \<16                       ↓ 1 ICS step       NA (*F*~eNO~ \>29 ppb)            No change

ICS: inhaled corticosteroid; ACQ: Asthma Control Questionnaire; LABA: long-acting β~2~-agonist; NA: not applicable.

###### 

Treatment steps for the exhaled nitric oxide fraction algorithm

  **ICS treatment step^\#^**              **β~2~-agonist treatment step^¶^**
  --------------------------------------- ---------------------------------------
  Step 1: 0                               Step 1: terbutalin as required
  Step 2: budesonide 100 µg twice daily   Step 2: formoterol 4.5 µg twice daily
  Step 3: budesonide 200 µg twice daily   Step 3: formoterol 9 µg twice daily
  Step 4: budesonide 400 µg twice daily   Step 4: formoterol 2×9 µg twice daily
  Step 5: budesonide 800 µg twice daily   

ICS: inhaled corticosteroid. ^\#^: based on exhaled nitric oxide fraction concentration; ^¶^: based on asthma control questionnaire score.

###### 

Asthma Control Questionnaire (ACQ) algorithm and treatment steps

                                   **ACQ score**                      **Treatment adjustment**
  ------------- ---------------------------------------------------- --------------------------
  **Level 1**                          \>1.5                                  ↑ 1 step
  **Level 2**                        0.75--1.5                               No change
  **Level 3**                          \<0.75                                 ↓ 1 step
                                   **Treatment**                     
  **Step 1**                   Terbutalin as required                
  **Step 2**               Budesonide 200 µg twice daily             
  **Step 3**               Budesonide 400 µg twice daily             
  **Step 4**     Budesonide 400 µg and formoterol 9 µg twice daily   
  **Step 5**     Budesonide 800 µg and formoterol 18 µg twice daily  

The day of enrolment (V1) was less than 1 week from when the patient completed a positive mannitol test and the participants were randomised and demographic data was recorded. All other tests, except mannitol provocation, were conducted and included measurement of *F*~eNO~, lung function tests, skin prick test, sputum and blood tests as well as pregnancy tests for the female participants. Furthermore, all participants fulfilled a series of written questionnaires including the ACQ, the mini Asthma Quality of Life Questionnaire (AQLQ) and the mini Rhinoconjuctivitis Quality of Life Questionnaire. The follow-up visits took place 8 (V2), 24 (V3) and 36 (V4) weeks after V1. In case of unscheduled visits due to exacerbations, the following visits were postponed by 2 weeks from last day of intake of the exacerbation treatment. At each follow-up visit *F*~eNO~, forced expiratory volume in 1 s (FEV1), ACQ, mannitol test, and sputum and blood tests were performed in all participants. Sample size calculation was conducted using a power at 80%, a significance level of 0.05 and a cut-off value of AHR of PD15 \>635 mg mannitol for loss of AHR of 80% in the *F*~eNO~ group *versus* 50% in the ACQ group. This resulted in 39 participants in each group.

Treatment algorithm {#s2b}
-------------------

Participants were started on different dosages of ICS, depending on their current treatment at randomisation. Steroid-naïve participants were initially treated with budesonide turbohaler (200 µg twice per day) and short-acting β~2~-agonist (terbutalin 0.5 mg as needed) from V1 to the following visit at V2, after which regulation was established based on the algorithm. Similarly, all participants already being treated with ICS at randomisation were continued on their current dosage for 8 weeks, after which they were regulated due to the algorithm. Thus, the treatment algorithms were introduced at V2. The initial dosage of ICS determined which treatment step each participant was regulated from at V2. Only participants already being treated with LABA prior to inclusion were continued on this treatment. In both treatment algorithms, the current dosage of ICS and β~2~-agonist determined which treatment step each patient was on at every visit. The regulation in treatment (decrease, increase or no change) was determined from this step ([tables 1](#TB1){ref-type="table"}--[3](#TB3){ref-type="table"}).

### *F*~eNO~ algorithm {#s2b1}

Participants randomised to this treatment algorithm were regulated in two sequences. First, their visit specific *F*~eNO~ value determined the regulation of ICS, and secondly their visit specific ACQ score determined the regulation of LABA. If a participant had a *F*~eNO~ concentration \<29 ppb as well as an ACQ score \>1.5, 4.5 µg formoterol was added ([tables 1](#TB1){ref-type="table"} and [2](#TB2){ref-type="table"}). The ICS steps and LABA steps were independent from each other. For patients taking LABA in the *F*~eNO~ group, ICS was never reduced to zero, but remained at 100 µg twice daily.

### ACQ algorithm {#s2b2}

Participants randomised to this algorithm were only regulated based on their visit specific ACQ. The algorithm did not contain regulations based on the participants visit specific *F*~eNO~ value. After a doubling of ICS, if a participant had a further increase in ACQ 4.5 µg formoterol was added ([table 3](#TB3){ref-type="table"}).

Lung function tests {#s2c}
-------------------

Lung function was measured using EasyOne (ndd Medical Technologies, Inc., Andover, MA, USA) according to European Respiratory Society (ERS) recommendations \[[@C15]\].

Exhaled nitric oxide {#s2d}
--------------------

*F*~eNO~ was measured using a nitric oxide analyser (NIOX VERO; Circassia Pharmaceuticals plc, Oxford, UK) during one full expiration according to American Thoracic Society/ERS recommendations \[[@C16]\]. Two measurements were performed at every visit, and the mean was used for analysis.

Mannitol bronchial provocation {#s2e}
------------------------------

Baseline FEV~1~ was used to calculate the percentage decline of FEV~1~ \[[@C17], [@C18]\]. The method of the mannitol provocation test has been described previously \[[@C17]\]. The test is supplied in kit form (Pharmaxis Ltd., French Forests, NSW, Australia). Response dose ratio (RDR) was calculated from the formula: FEV~1~ % decline/last dose of mannitol.

Sputum induction and cell count {#s2f}
-------------------------------

Sputum induction followed the ERS guidelines by using incremental concentrations of NaCl solutions (3%, 4% and 5%) Processing, including sputum and differential cell count, was performed according to study by P[avord]{.smallcaps} *et al*. \[[@C19]\].

Blood samples {#s2g}
-------------

The level of systemic inflammation was assessed using high-sensitivity C-reactive protein as a biomarker. Furthermore, the measurement of specific systemic inflammation was determined by the level of interleukin (IL)-6 and IL-8 which was measured using the ELISA technique (FLUOstar Omega, BMG Labtech, Offenburg, Germany).

Exacerbation {#s2h}
------------

Participants could be seen by the investigator in the outpatient clinic on a day-to-day basis in order to assess symptoms and severity in case of an exacerbation, which was defined as: 1) moderate exacerbation with increase of ACQ \>1.5 and was treated with doubling the ICS dosage over 14 days; and 2) severe exacerbation with ACQ \>2.0 and night-time awakenings which was treated with systemic steroids. In case of infection antibiotics were prescribed. The earliest date for the next study visit was 14 days after the last day of intake of exacerbation treatment.

Study outcomes {#s2i}
--------------

Primary study outcome was change in AHR to mannitol from 8 to 36 weeks measured as RDR. AHR was measured at all follow-up visits. Additional outcomes included accumulated ICS dose and number of asthma exacerbations.

Statistical analysis {#s2j}
--------------------

Outcomes were presented as mean±[sd]{.smallcaps} for approximately normally distributed variables and median (interquartile range; IQR) or geometric mean (95% CI) for variables with skewed distributions. Comparison of outcomes between groups were based on Chi-squared tests for categorical variables, t-tests for continuous variables with normal-like distributions, and Wilcoxon rank sum tests for continuous variables with skewed distributions. Change in continuous outcomes within groups was estimated, for the respective cases, by t-tests and Wilcoxon signed rank tests. Furthermore, spearman correlation coefficients were calculated. The same tests, with Wilcoxon signed rank tests in addition for continuous data with skewed distributions, were used within groups between visits. Change in outcome was further modelled by linear regression analyses, where change in the ACQ group was used as the reference. The crude and adjusted analyses were performed for the baseline level of the outcome. Model assumptions for linear regression were checked by the Shapiro--Wilk test and inspection of histograms and normal quantile plots of residuals. For some outcomes the assumptions were violated and the standard errors of the estimated effect were recalculated by robust linear regression to check if the violations were critical. The reported confidence intervals are based on the original linear regression analyses.

Analyses of the main outcome RDR were performed as both crude and log-transformed to correct the skewed distribution. The results are presented on the original scale.

Incidence rate-ratios of exacerbations were estimated using negative binomial regression.

Analyses were performed using Stata Statistical Software (release 14; StataCorp LP, College Station, TX, USA).

Results {#s3}
=======

A total of 80 outpatients with asthma and current AHR to mannitol were included in this RCT study concerning asthma management based on either *F*~eNO~ or ACQ ([figure 1](#F1){ref-type="fig"}). The mean±[sd]{.smallcaps} age of the 80 asthmatics was 38±15 years, 48 (60%) of the participants were female, 46 (58%) suffered from atopy, 16 (20%) were current smokers and 22 (28%) were former smokers. Throughout the course of the study, the total number of treatment requiring exacerbations was 20 in the *F*~eNO~ group and 25 in the ACQ group (p=0.6). Of these, four exacerbations in the *F*~eNO~ group were treated with systemic steroids and six exacerbations in the ACQ group were treated with systemic steroids.

Baseline characteristics for the *F*~eNO~ group and the ACQ group at 8 weeks are shown in [table 4](#TB4){ref-type="table"}. There were no statistically significant differences between the two treatment groups for AHR to mannitol (median PD15: *F*~eNO~ 195.7 (93.3--395.8) mg *versus* ACQ 269.7 (129.1--454.2) mg, p=0.4) or any demographic details at algorithm baseline at 8 weeks. No difference in median (IQR) ACQ between the two groups was found: (*F*~eNO~ 1.2 (0.2--1.6) *versus* ACQ 0.8 (0.4--2.0), p=0.7) or *F*~eNO~ (*F*~eNO~ 21 (13--32) ppb *versus* ACQ 22 (13--31) ppb, p=1.0). No difference was found in *F*~eNO~ between the two groups when current smokers were excluded from the analysis: *F*~eNO~ 24 (17--31) ppb *versus* ACQ 22 (14--30) ppb, p=0.4. Furthermore, no significant difference was found in FEV~1~ % predicted and forced vital capacity (FVC) % pred, whereas the FEV~1~/FVC ratio was significantly lower in the *F*~eNO~ group than the ACQ group (mean±[sd]{.smallcaps} 73.9±9.4% *versus* 78.8±8.1%, p=0.02) ([table 4](#TB4){ref-type="table"}). Systemic inflammation, measured by the level of high-sensitivity C-reactive protein, was similar in the two groups as was the use of ICS at enrolment (median (IQR); 400 (400--400) µg·day^−1^ in both groups). At baseline, 33 participants in the *F*~eNO~ group took 200 µg ICS twice daily and seven participants took 400 µg ICS twice daily. Six participants in the *F*~eNO~ group took LABA as a second controller. In the ACQ group one participant took 100 µg ICS twice daily, 32 participants took 200 µg twice daily and seven participants took 400 µg ICS twice daily. Five participants took LABA as a second controller daily in the ACQ group. Up and down titration in ICS treatment at each visit are shown in [figure 2](#F2){ref-type="fig"}.

###### 

Participant data at V2 (8 weeks)

                                   **ACQ group**     ***F***~**eNO**~ **group**   **p-value**^\#^
  ----------------------------- ------------------- ---------------------------- -----------------
  **Subjects n**                        36                       36              
  **Demographic details**^¶^                                                     
   Mean age years                   30 (24--46)             42 (27--52)                 0.1
   Height cm                           172±9                   173±8                    0.7
   Weight kg                        71 (62--85)             75 (66--80)                 0.5
   BMI kg·m^−2^                  24.2 (21.8--26.5)       24.3 (21.7--27.7)              0.7
   Atopy                              24 (67)                 22 (63)                   0.7
   Smoking                                                                              0.3
    Current                           5 (14)                  11 (28)            
    Ex                                12 (32)                 10 (25)            
    Never                             20 (54)                 19 (48)            
   Smoking history pack-years     6.0 (0.8--11.0)         10.0 (5.5--18.8)              0.2
  **Asthma-related QoL**                                                         
   ACQ                            1.2 (0.2--1.6)           0.8 (0.4--2.0)               0.7
   Mini AQLQ                      6.1 (5.2--6.5)           6.3 (5.4--6.7)               1.0
  **Spirometry**                                                                 
   RDR %·mg^−1^                  0.04 (0.02--0.06)       0.03 (0.02--0.06)              0.5
   Mean FEV~1~ L                     3.25±0.86               3.25±0.85                  1.0
   Mean FEV~1~ %                     92.4±11.3               94.7±16.2                  0.5
   Mean FVC L                        4.17±1.18               4.38±0.89                  0.4
   Mean FEV~1~/FVC %                 78.8±8.1                 73.8±9.4                 0.02
    *F*~eNO~ ppb                    21 (13--32)             22 (13--31)                 1.0
  **Present treatment**                                                          
   ICS use                            37 (97)                 40 (100)                  0.3
   ICS dose µg                    400 (400--400)           400 (400--400)               0.1
   LABA use                           6 (15)                   5 (13)                   0.8
   LABA dose µg                      9 (9--18)              18 (18--36)                 0.1
  **Inflammatory features**                                                      
   Leukocyte ×10^9^·L^−1^         6.5 (5.3--7.8)           6.5 (5.3--8.1)               0.8
   Eosinophil ×10^9^·L^−1^       0.14 (0.11--0.20)       0.18 (0.10--0.31)              0.5
   Neutrophil ×10^9^·L^−1^         4 (2.7--5.2)            3.3 (3.1--5.1)               0.9
   CRP mg·L^−1^                   1.1 (0.6--2.5)           1.0 (1.0--2.7)               0.9
   IgE kU·L^−1^                    99 (19--325)             98 (39--259)                1.0
   IL-6 pg·mg^−1^                 1.2 (0.8--2.1)           1.5 (1.0--2.2)               0.3
   IL-8 pg·mg^−1^                  110 (47--168)           116 (80--180)                0.6
  **Sputum inflammation**                                                        
   Eosinophils %                 0.38 (0.25--0.82)         0.88 (0.25--3)               0.1
   Neutrophils %                 38.0 (21.1--49.1)        28.0 (9.1--68.4)              0.9
   Macrophages %                  40.8 (17.3--57)        30.6 (18.8--64.3)              0.9
   Columnar epithelia %          11.4 (4.4--20.6)         12.1 (5.0--18.3)              0.8

Data are presented as median (interquartile range), mean±[sd]{.smallcaps} or n (%), unless otherwise stated. ACQ: Asthma Control Questionnaire; *F*~eNO~: exhaled nitric oxide fraction; BMI: body mass index; QoL: quality of life; AQLQ: Asthma Quality of Life Questionnaire; RDR: response dose ratio; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; ICS: inhaled corticosteroids; LABA: long-acting β~2~-agonist; CRP: C-reactive protein; Ig: immunoglobulin; IL: interleukin. ^\#^: based on Chi-squared tests, t-tests and Wilcoxon rank sum tests; ^¶^: data from 80 subjects (40 in each group).

![Number of participants at each level of inhaled corticosteroid (ICS) treatment at baseline in the exhaled nitric oxide fraction (*F*~eNO~) group and Asthma Control Questionnaire (ACQ) group, followed by the number of participants regulated according to the algorithms at visit 2 and 3, and finally the number of participants at each ICS treatment step in the two groups at final visit.](00147-2017.02){#F2}

The ACQ group did not significantly change in level of responsiveness to mannitol from V2 to V3, whereas the level of responsiveness in the *F*~eNO~ group decreased in this time period (p=0.04) ([figure 3](#F3){ref-type="fig"}). At visit 3, there was a statistically significant difference in responsiveness (RDR geometric mean (95% CI): *F*~eNO~ 0.02 (0.01--0.04) *versus* ACQ 0.05 (0.03--0.07), p=0.015) ([figure 3](#F3){ref-type="fig"}). The level of AHR was unchanged in the *F*~eNO~ group between V3 at 24 weeks and the end of study at 36 weeks (V4), whereas the ACQ group became less responsive between V3 and V4, resulting in similar responsiveness at the end of study in the two groups ([figure 3](#F3){ref-type="fig"}). The overall change in AHR in the algorithm period from week 8 to the end of study at week 36 was not significantly different between the two groups (mean difference RDR (95% CI): ACQ group as reference −0.02 (−0.05--0.02), p=0.3) ([table 5](#TB5){ref-type="table"}).

![Geometric mean (95% CI) response dose ratio (RDR) at each visit for the two intervention groups. Analyses of difference between groups at each visit are based on Wilcoxon rank sum tests. p-values at visits 2, 3 and 4 were p=0.53, p=0.015 and p=0.62, respectively. *F*~eNO~: exhaled nitric oxide fraction; ACQ: Asthma Control Questionnaire.](00147-2017.03){#F3}

###### 

Change in asthma profile from V2 (8 weeks) to V4 (36 weeks)

                                **Unadjusted *F***~**eNO**~ **group**   **Adjusted *F***~**eNO**~ **group**   **Adjusted p-value**
  ---------------------------- --------------------------------------- ------------------------------------- ----------------------
  **Asthma-related QoL**                                                                                     
   ACQ^\#^                                −0.2 (−0.7--0.3)                       −0.1 (−0.6--0.3)                     0.5
   Mini AQLQ^\#^                           0.2 (−0.3--0.6)                        0.1 (−0.3--0.6)                     0.6
  **Spirometry**                                                                                             
   RDR %·mg^−1\#,¶^                      0.16 (−0.14--0.46)                     −0.02 (−0.05--0.02)                   0.3
   Mean FEV~1~ L                         0.08 (−0.01--0.17)                     0.07 (−0.02--0.16)                    0.1
   Mean FEV~1~ %                           2.5 (−0.3--5.2)                        2.3 (−0.5--5.0)                     0.1
   Mean FVC L^\#^                        −0.10 (−0.22--0.03)                    −0.10 (−0.23--0.03)                   0.1
   Mean FEV~1~/FVC %^\#^                 0.03 (−0.00--0.05)                     0.02 (−0.00--0.05)                    0.1
    *F*~eNO~ ppb^\#^                        −17 (−36--2)                          −13 (−20-- −5)                     0.001
  **Present treatment**                                                                                      
   ICS dose µg^\#^                         −25 (−224--174)                         5 (−194--204)                      1.0
   LABA dose µg^\#^                        29 (−105--162)                         42 (−121--205)                      0.5
  **Inflammatory features**                                                                                  
   Leukocyte ×10^9^·L^−1\#^               −2.8 (−9.4--3.8)                       −3.1 (−9.8--3.6)                     0.4
   Eosinophil ×10^9^·L^−1\#^             −0.06 (−0.21--0.09)                      0 (−0.10--0.11)                     0.9
   Neutrophil ×10^9^·L^−1\#^              −0.2 (−1.2--0.9)                       −0.2 (−1.1--0.7)                     0.6
   CRP mg·L^−1\#^                         −0.7 (−2.5--1.1)                       −0.7 (−2.2--0.9)                     0.4
   IgE kU·L^−1^                             34 (−94--161)                          12 (−66--91)                       0.8
   IL-6 pg·mg^−1^                         −0.4 (−1.4--0.5)                       −0.2 (−0.7--0.3)                     0.4
   IL-8 pg·mg^−1^                       71.2 (−155.8--298.2)                   62.4 (−143.9--268.7)                   0.6
  **Sputum inflammation**                                                                                    
   Eosinophils %^\#^                    −9.14 (−18.50--0.21)                   −7.91 (−16.83--1.01)                   0.1
   Neutrophils %                          2.1 (−17.3--21.5)                      2.2 (−16.4--20.7)                    0.8
   Macrophages %                          2.1 (−12.9--17.2)                      1.2 (−12.3--14.7)                    0.9
   Columnar epithelia %^\#^               4.9 (−7.9--17.7)                       4.8 (−8.1--17.6)                     0.5

Data are presented as mean differences (95% CI) based on linear regression analyses, unless otherwise stated. Changes in the Asthma Control Questionnaire (ACQ) group were used as reference. Crude and adjusted analyses were performed for the baseline level of the outcome. *F*~eNO~: exhaled nitric oxide fraction; QoL: quality of life; AQLQ: Asthma Quality of Life Questionnaire; RDR: response dose ratio; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; ICS: inhaled corticosteroids; LABA: long-acting β~2~-agonist; CRP: C-reactive protein; Ig: immunoglobulin; IL: interleukin. ^\#^: in cases where the model assumptions were violated the effect estimates were checked with robust linear regression; ^¶^: analysis of 26 patients in the *F*~eNO~ group and 28 patients in the ACQ group.

At V3 *F*~eNO~ was significantly lower in the *F*~eNO~ group compared to the ACQ group (median (IQR): *F*~eNO~ 18 (12--21) ppb *versus* ACQ 31 (18--42) ppb, p=0.01) ([figure 4](#F4){ref-type="fig"}), although no significant difference was found when current smokers were excluded from the analysis (*F*~eNO~ 19 (16--25) ppb *versus* ACQ 29 (15--52) ppb, p=0.1). An association was found between the level of airway responsiveness RDR and the level of airway inflammation measured by *F*~eNO~ (r~s~=0.29, p=0.049) in the ACQ group. The *F*~eNO~ group showed a significant increase in lung function compared to the ACQ group between V2 and V3 (FEV~1~ % pred 4.0 (1.1--7.0), p\<0.05), calculated as mean difference (95% CI) based on linear regression analysis, with the ACQ group as reference (data not shown).

![Median (95% CI) exhaled nitric oxide fraction (*F*~eNO~) at each visit for the two intervention groups. Analyses of difference between groups at each visit are based on Wilcoxon rank sum tests. p-values at visits 2, 3 and 4 were p=1.00, p=0.01 and p=0.03, respectively. ACQ: Asthma Control Questionnaire.](00147-2017.04){#F4}

At the end of the study no significant difference between groups was found in AHR, RDR, FEV~1~ % pred, FVC % pred, inflammatory features, sputum eosinophils, ACQ or AQLQ ([table 6](#TB6){ref-type="table"}), whereas *F*~eNO~ was significantly lower in the *F*~eNO~ group compared to the ACQ group (median (IQR): *F*~eNO~ 15 (12--18) ppb *versus* 21 (14--29) ppb, p=0.03) ([figure 4](#F4){ref-type="fig"} and [table 6](#TB6){ref-type="table"}). This difference in *F*~eNO~ was not found when current smokers were excluded in the analysis (*F*~eNO~ 18 (13--23) *versus* ACQ 20 (14--29), p=0.2). No significant difference in asthma symptoms expressed in mean ACQ or ICS use was found between the two groups at any visit (data not shown).

###### 

Participant asthma profile at V4 (36 weeks)

                              **ACQ group**         ***F***~**eNO**~ **group**   **p-value***^\#^*
  --------------------------- --------------------- ---------------------------- -------------------
  **Subjects n**              29                    29                           
  **Quality of life**                                                            
   ACQ                        0.8 (0.4--2)          0.8 (0.4--1.8)               0.7
   Mini AQLQ                  6.2 (5.3--6.6)        6.2 (5.3--6.6)               0.5
  **Spirometry**                                                                 
   RDR %·mg^−1¶^              0.02 (0.01--0.06)     0.02 (0.01--0.06)            0.6
   FEV~1~ L                   3.15±0.96             3.33±0.85                    0.4
   FEV~1~ %                   89.7±12.4             94.6±15.4                    0.2
   FVC L                      4.17±1.22             4.41±0.96                    0.4
   FEV~1~/FVC %               75.8±8.1              75.3±8.4                     0.8
    *F*~eNO~ ppb              21 (14--29)           15 (12--18)                  0.03
  **Present treatment**                                                          
   ICS use                    17 (59)               20 (67)                      0.5
   ICS dose                   0 (0--800)            100 (0--600)                 0.8
   LABA use                   8 (28)                11 (37)                      0.5
   LABA dose                  18 (18--18)           18 (9--36)                   0.7
  **Inflammatory features**                                                      
   Leukocyte ×10^9^·L^−1^     6.0 (5.3--8.1)        6.0 (5.3--8.1)               0.4
   Eosinophil ×10^9^·L^−1^    0.14 (0.10--0.27)     0.17 (0.11--0.26)            0.7
   Neutrophil ×10^9^·L^−1^    3.50 (2.70--4.10)     2.90 (2.50--4.30)            0.3
   CRP mg·L^−1^               1.0 (1.0--2.0)        1.0 (1.0--1.4)               0.8
   IgE kU·L^−1^               79 (7--235)           56 (15--211)                 0.9
   IL-6 pg·mg^−1^             1.5 (0.9--2.4)        1.3 (0.9--2.1)               0.7
   IL-8 pg·mg^−1^             106.9 (33.0--248.1)   127.7 (61.6--222.3)          0.6
  **Sputum inflammation**                                                        
   Eosinophils %              0.75 (0--3.25)        1.38 (0.25--2.75)            0.7
   Neutrophils %              21.8 (11.3--54.5)     25.6 (13.6--65.6)            0.7
   Macrophage %               42.8 (12.3--67.0)     35.1 (19.5--58.6)            0.5
   Columnar epithelia %       5.5 (1.8--26.5)       15 (5.3--30.3)               0.2

Data are presented as median (interquartile range), mean±[sd]{.smallcaps} or n (%), unless otherwise stated. ACQ: Asthma Control Questionnaire; *F*~eNO~: exhaled nitric oxide fraction; AQLQ: Asthma Quality of Life Questionnaire; RDR: response dose ratio; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; ICS: inhaled corticosteroids; LABA: long-acting β~2~-agonist; CRP: C-reactive protein; Ig: immunoglobulin; IL: interleukin. ^\#^: based on Chi-squared tests, t-tests and Wilcoxon rank sum tests; ^¶^: analysis of 26 patients in the *F*~eNO~ group and 28 patients in the ACQ group.

Discussion {#s4}
==========

This double-blinded RCT evaluated the use of *F*~eNO~ *versus* ACQ as monitoring tools for asthma treatment of patients with possible Th2 asthma and a positive mannitol test and showed that asthma control indicated by a lower level of airway response to mannitol was the same after 36 weeks of treatment in the two groups; however, control was achieved faster when *F*~eNO~ was used as a monitoring tool. The fast improvement in asthma control in the *F*~eNO~ group was supported by the results of increase in lung function and decrease in *F*~eNO~ for this group of patients at week 24.

Our study was powered to assess response to mannitol as a surrogate variable for asthma control. Previous studies investigating *F*~eNO~ as a monitoring tool all used exacerbations as the primary outcome, including a less homogenous asthma group than in the present study \[[@C14], [@C20], [@C21]\]. E[ssat]{.smallcaps} *et al*. \[[@C22]\] showed a high level of heterogeneity in the definition of asthma exacerbations as outcome illustrated in a systematic review. When using RDR as a primary outcome, we used an objective measurement to assess the level of asthmatic status. We thereby avoided the risk of bias associated with patient self-reported exacerbations as reported by S[mith]{.smallcaps} *et al*. \[[@C21]\]. In the present study only exacerbations requiring treatment of doubling of ICS and/or oral corticoid steroids and/or antibiotics were included, which resulted in a low number of registered exacerbations. A total of 10 exacerbations (four in the *F*~eNO~ group and six in the ACQ group) required treatment with systemic steroid. This might have had an effect on the final result, but the following visit was postponed to assure wash-out.

P[owell]{.smallcaps} *et al*. \[[@C14]\] showed a significant reduction in exacerbations in pregnant women when using the *F*~eNO~ algorithm compared to the ACQ algorithm. They prepared an optimised *F*~eNO~ algorithm based on evidence from previous studies. We used the same algorithm in our RCT investigating real-life patients with a confirmed asthma diagnosis prior to enrolment. In the study by P[owell]{.smallcaps} *et al*. \[[@C14]\] participants were seen monthly in 5--6 months resulting in a higher frequency of regulation in treatment than in our study where regulation was made at two visits. This might have had an effect on the final use of ICS as there is a difference in dose increments in the two algorithms. However, no significant difference in ICS treatment was seen between the two groups at any visit. Eosinophilic asthma (Th2 high) is associated with elevated levels of *F*~eNO~ and AHR towards mannitol \[[@C6]--[@C8], [@C23]\], thus the group of patients in this study seemingly have eosinophilic asthma. This current homogenous group of asthma patients is different from former studies, with doctor\'s diagnosis of asthma only and a mix of airway inflammation. The support for Th2 asthma was that a high *F*~eNO~ was found in a substantial number of both steroid-naïve and steroid-treated participants at baseline. Overall, we found that all participants in this group had improved asthma control from baseline to the end of study, assessed by AHR towards mannitol.

To obtain statistical power we calculated that 39 participants were required in each group, thus we included 40 participants in each group. However, drop-out and exclusions in the course of the study resulted in 29 participants in each group at the end of the study. This is a limitation of the study and the final results might have been affected by this lack of statistical power. We did not register adherence in this study. This is a limitation of the study. The majority of participants entered the study with yearlong diagnoses of asthma and were used to treatment with ICS and other inhaled asthma medication, suggesting a continuous and similar, but possibly inadequate, adherence comparable to the background asthma patient population, which would not be a surprise as this is a real-life study. Furthermore, as a real-life study we did not have counters on the participants' inhalers, but they were asked to take the medication as prescribed. At each visit, participants were asked about daily use of medication and the clinical staff repeated instructions for medication use at each visit to ensure best possible adherence, as well as device education. We included former current smokers in the study. Previous studies found that smoking has short- and long-term effects on *F*~eNO~ \[[@C24]\]. *F*~eNO~ values in this study might have been affected by smoking, however, no significant difference in smoking status was seen between the two groups. Finally, steroid-naïve patients were included in the study and since they were referred for specialist care due to asthma symptoms and uncontrolled disease, a recommended low dose of ICS (200 µg twice daily) was prescribed. This could have affected the speed of asthma control when using the algorithm, as some of the asthma control had already been gained at week 8 (V2) in this group of patients.

As a secondary outcome we investigated and found an association between increased AHR to mannitol and elevated *F*~eNO~ level at week 24 (V3) in the ACQ group. This suggests a correlation between AHR and the level of *F*~eNO~. We observed an overall low number of exacerbations in this study, supporting the general use of a follow-up algorithm (*F*~eNO~ or ACQ).

No significant difference in symptom score or systemic inflammation was seen at any time during the study between the two groups. In addition, the level of lung function was found to be similar in the two groups. The use of ICS was reduced in the ACQ group more steeply than in the *F*~eNO~ group, although a number of participants with elevated AHR were found at the end of the study in the ACQ group. This indicates that symptom control not always corresponds to the level of inflammation or objective measurements of asthmatic status. When regulating asthma treatment, objective measures should be taken into account even though this study did not show that the regulation could be made based on *F*~eNO~ level only.

This study did not include patients with high *F*~eNO~ exclusively. However, all participants were receiving treatment with ICS at time of randomisation (except three participants in the ACQ group) which could give a lower baseline *F*~eNO~ value than if all participants were steroid naïve. Included patients with low *F*~eNO~ and AHR to mannitol might represent a different phenotype than the patients with high *F*~eNO~ and AHR to mannitol. This possible inclusion of different phenotypes represents a limitation of the study. Future studies might be directed even more to this issue, ensuring inclusion of asthma patients with an eosinophilic phenotype only. However, the strengths of the study are that all included patients had asthma with symptoms, a doctor\'s diagnosis of asthma and a positive mannitol test.

In conclusion, a more rapid improvement in asthma control was observed when using a *F*~eNO~ guided treatment algorithm compared to an ACQ guided treatment algorithm, but level of asthma control was similar in the two groups after 9 months of treatment.

This study is registered at [www.ClinicalTrials.gov](www.ClinicalTrials.gov) with identifier number NCT01978678. Individual de-identified participant data will not be shared. No additional documents will be available for this trial at any time.
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